Nanoparticle-based strategies for immune modulation and reorganization in the tumor microenvironment to combat cancer cells
5 affiliations
- 1Faculty of Basic Sciences, University of Maragheh, Iran. Electronic address: [email protected]
- 2Department of Veterinary Medicine, Islamic Azad University of Urmia, Urmia, Iran. Electronic address: [email protected]
- 3Department of Cell and Molecular Biology, Faculty of Science, University of Mazandaran, Iran
- 4Department of Dentistry, Tehran Medical Sciences branch of Islamic Azad University, Tehran, Iran. Electronic address: [email protected]
- 5Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran; Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: [email protected]
Abstract
The tumor microenvironment (TME) is a complex ecosystem that weakens the effectiveness of cancer treatments, especially immunotherapy. Characterized by hypoxia, extracellular acidosis, aberrant enzyme activity, dense extracellular matrix (ECM), and an abundance of immunosuppressive cells, including tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs), the TME creates formidable barriers to drug delivery and immune activation. Nanoparticles (NPs) have become adaptable tools for addressing these issues by facilitating accurate targeting and reprogramming of immune cells while concurrently restructuring the TME. Engineered NPs can deliver immunomodulators directly to TAMs, dendritic cells, or T cells, reversing immune exhaustion and promoting anti-tumor responses. Beyond immune cell engagement, NPs are increasingly designed to respond to or correct pathological TME cues: hypoxia-activated or oxygen-generating NPs alleviate oxygen deprivation and reduce hypoxia-inducible factor 1-alpha (HIF-1α)-driven immunosuppression; pH-sensitive carriers exploit extracellular acidosis for tumor-selective drug release; enzyme-responsive systems enhance penetration and specificity; and co-delivery of ECM-degrading enzymes improves NP diffusion and T-cell infiltration. Moreover, multifunctional nanoplatforms integrating immune activation with TME normalization, such as simultaneous TAM repolarization, vascular normalization, and checkpoint blockade, demonstrate synergistic efficacy. This review comprehensively examines how nanotechnology bridges the gap between TME biology and therapeutic intervention, highlighting advances in NP design, mechanistic insights into TME remodeling, and emerging clinical translation.
Related
- Nanoplatform-Enhanced Therapies for Adenoid Cystic Carcinoma: Integrating Pathobiology, Microenvironment Modulation, and Synergistic Treatment Strategies
- Gamma irradiation-induced morphological and optical modulation in colloidal lithography-fabricated gold nanoparticle arrays
- A Smartphone-Based Silver Nanoparticle Assay for Detecting Enhanced Gamma-Aminobutyric Acid Content in Germinated Rice via Metabolic Modulation
- Nanotechnology integration in oncology for advanced nanoparticle based strategies in targeted cancer diagnosis and treatment
- Intranasal nano-immunotherapy for glioma: bypassing the blood–brain barrier, reprogramming the immune microenvironment, and bridging preclinical validation
BibTeX
@article{azhdarifam2026nanoparticlebased,
title = {{Nanoparticle-based strategies for immune modulation and reorganization in the tumor microenvironment to combat cancer cells}},
author = {Samira Azhdarifam and Mahtab Metanat and Nadia Ghobeishavi and Sepehr Nouroloyouni and Rana Jahanban‐Esfahlan},
journal = {Biomedicine \& Pharmacotherapy},
year = {2026},
month = jun,
doi = {10.1016/j.biopha.2026.119529},
url = {https://doi.org/10.1016/j.biopha.2026.119529},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Nanoparticle-based strategies for immune modulation and reorganization in the tumor microenvironment to combat cancer cells
AU - Samira Azhdarifam
AU - Mahtab Metanat
AU - Nadia Ghobeishavi
AU - Sepehr Nouroloyouni
AU - Rana Jahanban‐Esfahlan
PY - 2026
DA - 2026/06/10
JO - Biomedicine & Pharmacotherapy
DO - 10.1016/j.biopha.2026.119529
UR - https://doi.org/10.1016/j.biopha.2026.119529
AB - The tumor microenvironment (TME) is a complex ecosystem that weakens the effectiveness of cancer treatments, especially immunotherapy. Characterized by hypoxia, extracellular acidosis, aberrant enzyme activity, dense extracellular matrix (ECM), and an abundance of immunosuppressive cells, including tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs), the TME creates formidable barriers to drug delivery and immune activation. Nanoparticles (NPs) have become adaptable tools for addressing these issues by facilitating accurate targeting and reprogramming of immune cells while concurrently restructuring the TME. Engineered NPs can deliver immunomodulators directly to TAMs, dendritic cells, or T cells, reversing immune exhaustion and promoting anti-tumor responses. Beyond immune cell engagement, NPs are increasingly designed to respond to or correct pathological TME cues: hypoxia-activated or oxygen-generating NPs alleviate oxygen deprivation and reduce hypoxia-inducible factor 1-alpha (HIF-1α)-driven immunosuppression; pH-sensitive carriers exploit extracellular acidosis for tumor-selective drug release; enzyme-responsive systems enhance penetration and specificity; and co-delivery of ECM-degrading enzymes improves NP diffusion and T-cell infiltration. Moreover, multifunctional nanoplatforms integrating immune activation with TME normalization, such as simultaneous TAM repolarization, vascular normalization, and checkpoint blockade, demonstrate synergistic efficacy. This review comprehensively examines how nanotechnology bridges the gap between TME biology and therapeutic intervention, highlighting advances in NP design, mechanistic insights into TME remodeling, and emerging clinical translation.
SN - 0753-3322
SN - 1950-6007
ER -